Journal of Clinical Endocrinology & Metabolism, Vol 81, 3923-3929, Copyright © 1996 by Endocrine Society

ARTICLES

Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values

JH Brossard, M Cloutier, L Roy, R Lepage, M Gascon-Barre and P D'Amour
Centre de Recherche Clinique Andre-Viallet, Hopital Saint-Luc, Montreal, Quebec, Canada. h/rossard//article/nonpth.184

A molecular form of PTH different from PTH-(1-84) and present in normal serum is recognized by two-site intact (I-) PTH assays; it responds to Ca2+ changes in the same way that PTH carboxyl-terminal fragments do. To evaluate the impact of this finding, we have compared basal, stimulated, and nonsuppressible I-PTH values in 14 normal subjects and 15 renal failure patients, subdivided into 8 patients with low (< 12 pmol/L; LBI) and 7 with high (> 12 pmol/L; HBI) basal I-PTH. Samples obtained under various calcemic conditions in these 3 groups were further fractionated by high performance liquid chromatography (HPLC) and assayed for I-PTH, and the various peaks observed were quantitated by planimetry. Differences among the 3 groups were reinterpreted knowing the exact composition of I-PTH. Basal I-PTH was greatly increased in HBI (mean +/- SD, 44.1 +/- 38.6 pmol/L) compared to that in normal subjects (2.5 +/- 0.8 pmol/L; P < 0.001) or LBI (6.1 +/- 2.4 pmol/L; P < 0.001); the difference was less in these last 2 groups (P < 0.01). Similar differences were observed for stimulated and nonsuppressible I-PTH, except for stimulated I-PTH, which was similar in normal and LBI subjects. Two I-PTH HPLC molecular forms accounted for I-PTH immunoreactivity in the 3 groups. In normal subjects, PTH-(1- 84) accounted for 74.9 +/- 4.3%, 79.0 +/- 3.0%, and 87.2 +/- 1.0% of I- PTH in hyper-, normo-, and hypocalcemia, respectively, but only for 44.6 +/- 2.5%, 50.5 +/- 0.7%, and 63.6 +/- 0.1% in renal failure patients, with similar results in HBI and LBI. The accumulation of a non-(1-84) PTH peak accounted for the difference between normal subjects and renal failure patients. When basal, stimulated, and nonsuppressible I-PTH values were separated into their 2 components, prior differences between HBI and LBI or normal subjects remained unchanged because of very high I-PTH values in HBI, but differences between normal and LBI subjects were entirely explained by the accumulation of the non-(1-84) PTH peak [basal, 3.0 +/- 1.2 vs. 0.5 +/- 0.2 pmol/L (P < 0.001); stimulated, 6.8 +/- 2.3 vs. 2.3 +/- 1.0 pmol/L (P < 0.001); nonsuppressible, 1.3 +/- 0.7 vs. 0.2 +/- 0.08 pmol/L (P < 0.001)]; PTH-(1-84) values were similar (basal, 3.1 +/- 1.2 vs. 2.0 +/- 0.6 pmol/L; stimulated, 12.0 +/- 3.9 vs. 15.5 +/- 6.6 pmol/L; nonsuppressible, 1.1 +/- 0.6 vs. 0.52 +/- 0.22 pmol/L). Thus, a non-(1- 84) PTH molecular form detected by two-site I-PTH assays accumulates in renal failure and accounts for a larger proportion of I-PTH than that in normal subjects. Levels of I-PTH 1.57 times higher than those in normocalcemic subjects are thus required in renal failure to achieve similar PTH-(1-84) concentrations. The composition of I-PTH is also identical in all hemodialyzed patients.

This article has been cited by other articles:

				C. Valle, M. Rodriguez, R. Santamaria, Y. Almaden, M. E. Rodriguez, S. Canadillas, A. Martin-Malo, and P. Aljama Cinacalcet Reduces the Set Point of the PTH-Calcium Curve J. Am. Soc. Nephrol., December 1, 2008; 19(12): 2430 - 2436. [Abstract] [Full Text] [PDF]

				M. E. McGee-Lawrence, H. V. Carey, and S. W. Donahue Mammalian hibernation as a model of disuse osteoporosis: the effects of physical inactivity on bone metabolism, structure, and strength Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2008; 295(6): R1999 - R2014. [Abstract] [Full Text] [PDF]

				J. D. Hernandez, K. Wesseling, R. Pereira, B. Gales, R. Harrison, and I. B. Salusky Technical Approach to Iliac Crest Biopsy Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(Supplement_3): S164 - S169. [Abstract] [Full Text] [PDF]

				H. Komaba, Y. Takeda, J. Shin, R. Tanaka, T. Kakuta, Y. Tominaga, and M. Fukagawa Reversed whole PTH/intact PTH ratio as an indicator of marked parathyroid enlargement: five case studies and a literature review NDT Plus, August 1, 2008; 1(suppl_3): iii54 - iii58. [Abstract] [Full Text] [PDF]

				T. B. Drueke and M. Fukagawa Whole or Fragmentary Information on Parathyroid Hormone? Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1106 - 1107. [Full Text] [PDF]

				A. J. Felsenfeld, M. Rodriguez, and E. Aguilera-Tejero Dynamics of Parathyroid Hormone Secretion in Health and Secondary Hyperparathyroidism Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1283 - 1305. [Abstract] [Full Text] [PDF]

				M.-C. Monier-Faugere, H. Mawad, and H. H. Malluche Opposite Effects of Calcitriol and Paricalcitol on the Parathyroid Hormone-(1-84)/Large Carboxy-Terminal-Parathyroid Hormone Fragments Ratio in Patients with Stage 5 Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1255 - 1260. [Abstract] [Full Text] [PDF]

				K. J. Martin and E. A. Gonzalez Metabolic Bone Disease in Chronic Kidney Disease J. Am. Soc. Nephrol., March 1, 2007; 18(3): 875 - 885. [Abstract] [Full Text] [PDF]

				L. M. Henrich, A. D. Rogol, P. D'Amour, M. A. Levine, J. B. Hanks, and D. E. Bruns Persistent Hypercalcemia After Parathyroidectomy in an Adolescent and Effect of Treatment With Cinacalcet HCl Clin. Chem., December 1, 2006; 52(12): 2286 - 2293. [Abstract] [Full Text] [PDF]

				T. Cantor, Z. Yang, N. Caraiani, and E. Ilamathi Lack of Comparability of Intact Parathyroid Hormone Measurements among Commercial Assays for End-Stage Renal Disease Patients: Implication for Treatment Decisions Clin. Chem., September 1, 2006; 52(9): 1771 - 1776. [Abstract] [Full Text] [PDF]

				E. Lewin and K. Olgaard Parathyroidectomy vs calcimimetics for treatment of persistent hyperparathyroidism after kidney transplantation Nephrol. Dial. Transplant., July 1, 2006; 21(7): 1766 - 1769. [Full Text] [PDF]

				J. Huan, K. Olgaard, L. B. Nielsen, and E. Lewin Parathyroid Hormone 7-84 Induces Hypocalcemia and Inhibits the Parathyroid Hormone 1-84 Secretory Response to Hypocalcemia in Rats with Intact Parathyroid Glands J. Am. Soc. Nephrol., July 1, 2006; 17(7): 1923 - 1930. [Abstract] [Full Text] [PDF]

				C. Bieglmayer, K. Kaczirek, G. Prager, and B. Niederle Parathyroid Hormone Monitoring during Total Parathyroidectomy for Renal Hyperparathyroidism: Pilot Study of the Impact of Renal Function and Assay Specificity Clin. Chem., June 1, 2006; 52(6): 1112 - 1119. [Abstract] [Full Text] [PDF]

				P. A. Friedman and W. G. Goodman PTH(1-84)/PTH(7-84): a balance of power Am J Physiol Renal Physiol, May 1, 2006; 290(5): F975 - F984. [Abstract] [Full Text] [PDF]

				K. Olgaard and E. Lewin Can Hyperparathyroid Bone Disease Be Arrested or Reversed? Clin. J. Am. Soc. Nephrol., May 1, 2006; 1(3): 367 - 373. [Abstract] [Full Text] [PDF]

				T. Arakawa, P. D'Amour, L. Rousseau, J.-H. Brossard, M. Sakai, H. Kasumoto, N. Igaki, T. Goto, T. Cantor, and M. Fukagawa Overproduction and Secretion of a Novel Amino-Terminal Form of Parathyroid Hormone from a Severe Type of Parathyroid Hyperplasia in Uremia Clin. J. Am. Soc. Nephrol., May 1, 2006; 1(3): 525 - 531. [Abstract] [Full Text] [PDF]

				K. Kaczirek, G. Prager, P. Riss, G. Wunderer, R. Asari, C. Scheuba, C. Bieglmayer, and B. Niederle Novel parathyroid hormone (1-84) assay as basis for parathyroid hormone monitoring in renal hyperparathyroidism. Arch Surg, February 1, 2006; 141(2): 129 - 134. [Abstract] [Full Text] [PDF]

				P. D'Amour, A. Rakel, J.-H. Brossard, L. Rousseau, C. Albert, and T. Cantor Acute Regulation of Circulating Parathyroid Hormone (PTH) Molecular Forms by Calcium: Utility of PTH Fragments/PTH(1-84) Ratios Derived from Three Generations of PTH Assays J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 283 - 289. [Abstract] [Full Text] [PDF]

				J. T Potts Parathyroid hormone: past and present J. Endocrinol., December 1, 2005; 187(3): 311 - 325. [Abstract] [Full Text] [PDF]

				T. Kawata, Y. Imanishi, K. Kobayashi, N. Onoda, Y. Takemoto, H. Tahara, S. Okuno, E. Ishimura, T. Miki, T. Ishikawa, et al. Direct in Vitro Evidence of Extracellular Ca2+-Induced Amino-Terminal Truncation of Human Parathyroid Hormone (1-84) by Human Parathyroid Cells J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5774 - 5778. [Abstract] [Full Text] [PDF]

				T. M. Murray, L. G. Rao, P. Divieti, and F. R. Bringhurst Parathyroid Hormone Secretion and Action: Evidence for Discrete Receptors for the Carboxyl-Terminal Region and Related Biological Actions of Carboxyl- Terminal Ligands Endocr. Rev., February 1, 2005; 26(1): 78 - 113. [Abstract] [Full Text] [PDF]

				P. D'Amour, J.-H. Brossard, A. Rakel, L. Rousseau, C. Albert, and T. Cantor Evidence That the Amino-Terminal Composition of Non-(1-84) Parathyroid Hormone Fragments Starts before Position 19 Clin. Chem., January 1, 2005; 51(1): 169 - 176. [Abstract] [Full Text] [PDF]

				S. A. Santini, C. Carrozza, C. Vulpio, E. Capoluongo, G. Luciani, P. Lulli, B. Giardina, and C. Zuppi Assessment of Parathyroid Function in Clinical Practice: Which Parathyroid Hormone Assay Is Better? Clin. Chem., July 1, 2004; 50(7): 1247 - 1250. [Full Text] [PDF]

				V. Carnevale, S. Dionisi, I. Nofroni, E. Romagnoli, F. Paglia, S. De Geronimo, J. Pepe, G. Clemente, G. Tonnarini, and S. Minisola Potential Clinical Utility of a New IRMA for Parathyroid Hormone in Postmenopausal Patients with Primary Hyperparathyroidism Clin. Chem., March 1, 2004; 50(3): 626 - 631. [Abstract] [Full Text] [PDF]

				M. Inaba, K. Nakatsuka, Y. Imanishi, M. Watanabe, Y. Mamiya, E. Ishimura, and Y. Nishizawa Technical and Clinical Characterization of the Bio-PTH (1-84) Immunochemiluminometric Assay and Comparison with a Second-Generation Assay for Parathyroid Hormone Clin. Chem., February 1, 2004; 50(2): 385 - 390. [Abstract] [Full Text] [PDF]

				F. R. Bringhurst Circulating Forms of Parathyroid Hormone: Peeling Back the Onion Clin. Chem., December 1, 2003; 49(12): 1973 - 1975. [Full Text] [PDF]

				P. D'Amour, J.-H. Brossard, L. Rousseau, L. Roy, P. Gao, and T. Cantor Amino-Terminal Form of Parathyroid Hormone (PTH) with Immunologic Similarities to hPTH(1-84) Is Overproduced in Primary and Secondary Hyperparathyroidism Clin. Chem., December 1, 2003; 49(12): 2037 - 2044. [Abstract] [Full Text] [PDF]

				J. C. Estepa, I. Lopez, A. J. Felsenfeld, P. Gao, T. Cantor, M. Rodriguez, and E. Aguilera-Tejero Dynamics of secretion and metabolism of PTH during hypo- and hypercalcaemia in the dog as determined by the 'intact' and 'whole' PTH assays Nephrol. Dial. Transplant., June 1, 2003; 18(6): 1101 - 1107. [Abstract] [Full Text] [PDF]

				H. Reichel, A. Esser, H.-J. Roth, and H. Schmidt-Gayk Influence of PTH assay methodology on differential diagnosis of renal bone disease Nephrol. Dial. Transplant., April 1, 2003; 18(4): 759 - 768. [Abstract] [Full Text] [PDF]

				W. G. Goodman, I. B. Salusky, and H. Juppner New lessons from old assays: parathyroid hormone (PTH), its receptors, and the potential biological relevance of PTH fragments Nephrol. Dial. Transplant., October 1, 2002; 17(10): 1731 - 1736. [Full Text] [PDF]

				C. Bieglmayer, G. Prager, and B. Niederle Kinetic Analyses of Parathyroid Hormone Clearance as Measured by Three Rapid Immunoassays during Parathyroidectomy Clin. Chem., October 1, 2002; 48(10): 1731 - 1738. [Abstract] [Full Text] [PDF]

				E. Lewin, B. Garfia, F. L. Recio, M. Rodriguez, and K. Olgaard Persistent Downregulation of Calcium-Sensing Receptor mRNA in Rat Parathyroids when Severe Secondary Hyperparathyroidism Is Reversed by an Isogenic Kidney Transplantation J. Am. Soc. Nephrol., August 1, 2002; 13(8): 2110 - 2116. [Abstract] [Full Text] [PDF]

				J.-P. Casez, K. Lippuner, F. F. Horber, A. Montandon, and P. Jaeger Changes in bone mineral density over 18 months following kidney transplantation: the respective roles of prednisone and parathyroid hormone Nephrol. Dial. Transplant., July 1, 2002; 17(7): 1318 - 1326. [Abstract] [Full Text] [PDF]

				I. B. SALUSKY and W. G. GOODMAN Adynamic Renal Osteodystrophy: Is There a Problem? J. Am. Soc. Nephrol., September 1, 2001; 12(9): 1978 - 1985. [Full Text] [PDF]

				A. Fournier, M. E. C. Solal, R. Oprisiu, H. Mazouz, P. Morinire, G. Choukroun, and R. Bouillon Optimal Range of Plasma Concentration of True 1-84 Parathyroid Hormone in Patients on Maintenance Dialysis J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1840 - 1841. [Full Text]

				W. G. Goodman, M. R. John, H. Jüppner, and I. B. Salusky Parathyroid Hormone-Immunoradiometric Assays as Noninvasive Predictors of Renal Osteodystrophy: The Need for Bone Histomorphometric Validation J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1841 - 1842. [Full Text]

				L. Nguyen-Yamamoto, L. Rousseau, J.-H. Brossard, R. Lepage, and P. D’amour Synthetic Carboxyl-Terminal Fragments of Parathyroid Hormone (PTH) Decrease Ionized Calcium Concentration in Rats by Acting on a Receptor Different from the PTH/PTH-Related Peptide Receptor Endocrinology, April 1, 2001; 142(4): 1386 - 1392. [Abstract] [Full Text]

				H. Cardinal, J.-H. Brossard, L. Roy, R. Lepage, L. Rousseau, and P. D’Amour The Set Point of Parathyroid Hormone Stimulation by Calcium Is Normal in Progressive Renal Failure J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3839 - 3844. [Abstract] [Full Text]

				G. W. Maier, M. E. Kreis, W. Renn, P. L. Pereira, H. U. Häring, and H. D. Becker Parathyroid Hormone after Adenectomy for Primary Hyperparathyroidism. A Study of Peptide Hormone Elimination Kinetics in Humans J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3852 - 3856. [Abstract] [Full Text]

				W. G. Goodman, J. D. Veldhuis, T. R. Belin, A. J. Van Herle, H. Juppner, and I. B. Salusky Calcium-Sensing by Parathyroid Glands in Secondary Hyperparathyroidism J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2765 - 2772. [Abstract] [Full Text]

				R. Lepage, L. Roy, J.-H. Brossard, L. Rousseau, C. Dorais, C. Lazure, and P. D'Amour A non-(1–84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples Clin. Chem., April 1, 1998; 44(4): 805 - 809. [Abstract] [Full Text] [PDF]